Noom is the industry’s most advanced GLP-1 Companion.
Lasting change made easy.
MAXIMIZING WEIGHT LOSS SUCCESS
Noom provides personalized lifestyle guidance and digital health tools that enhance the effectiveness of GLP-1 medications, helping members achieve long term results.
SUSTAINED RESULTS THROUGH TAILORED BEHAVIOR-CHANGE
Noom uses proven behavior change strategies to support members throughout their entire medication journey.
BOOSTING ADHERENCE TO REDUCE GLP-1 WASTAGE
Noom help members surmount the challenges that come with adhering to GLP-1 therapy, allowing them to maximize its benefits.
Noom’s GLP-1 Companion makes long-term health a reality.
Intelligent med tracking and dosing, guided by the Noom app, to support clinician-led treatment.
Individualized protein and macro targets, with easy photo-based meal logging.
Tailored, approachable workouts designed for everyone to preserve and build lean muscle.
Understand and track body composition metrics like lean mass and body fat percentage.
Movement tips, side-effect support, and more..
Predictive insights guide healthy choices to support blood sugar control.
Digital health support linked to real results.
Weight loss outcomes by engagement quartile
*Based on a January 2026 analysis of 14,210 Noom GLP-1Rx program members who joined between December 2024 and February 2025 and logged weight during a measurement week (4, 8, 16, 40 weeks)
Total months persisted by engagement quartile
*Based on a January 2026 analysis of 30,239 Noom GLP-1Rx program members who joined between December 2024 and February 2025
Frequently Asked Questions
- Weight Loss and Engagement: January 2026 analysis of 14,203 Noom GLP-1Rx Program members who started a GLP-1Rx plan between December 2024 and February 2025 and logged weight during a measurement week (4, 8, 16, 40 weeks). Engagement quartiles compare the frequency of Noom app opens (capped at 20 app opens per day) among users who weighed in within the specified measurement week. Weight loss across this period was stratified by quartiles of engagement (Quartiles of average total app opens at 40 weeks: Q1 = 244.7 , Q4 = 2,162.2). Quartiles showed significantly different weight loss, p < 0.001.
- Medication program persistence and engagement: January 2026 analysis of 30,239 Noom GLP-1Rx Program members who started a GLP-1Rx plan between December 2024 and February 2025, evaluating program persistence by engagement quartile. Results based on users stratified into engagement quartiles during a trial period and then tracking the duration of their paid program membership (Months of persistence by engagement quartile: Q1 = 2.8 , Q4 = 6.2). Quartiles showed significantly different persistence, p = < .001.